

DRUG NAME: Dactinomycin**SYNONYM(S)**¹: actinomycin D, actinomycin C1**COMMON TRADE NAME(S)**: COSMEGEN®**CLASSIFICATION**: antitumour antibiotic, cytotoxic²*Special pediatric considerations are noted when applicable, otherwise adult provisions apply.***MECHANISM OF ACTION:**

Dactinomycin is an antineoplastic antibiotic derived from *Streptomyces parvullus*.³ Stable complexes are formed with DNA through intercalation and DNA-dependent RNA synthesis is selectively inhibited.^{1,3,4} Protein and DNA synthesis are inhibited to a lesser extent.⁴ Dactinomycin is cell cycle phase-nonspecific¹. Dactinomycin is an immunosuppressive agent.⁴

PHARMACOKINETICS:

Oral Absorption	poor ⁴	
Distribution	rapid; high concentrations in bone marrow and nucleated cells ⁴ ; extensively bound to body tissues	
	cross blood brain barrier?	<10%
	volume of distribution	no information found
	plasma protein binding	not highly protein bound
Metabolism	minimal	
	active metabolite(s)	none
	inactive metabolite(s) ⁴	small amounts of monolactones have been recovered in urine
Excretion	rapidly cleared from plasma (85% within 2 min)	
	urine	12-20% of dose recovered within 24 h, 15% of dose recovered unchanged after 1 week
	feces	50-90% of dose excreted in bile within 24 h, 15% of dose recovered after 1 week
	terminal half life	36 hours, possibly prolonged with hepatic dysfunction
	clearance	no information found

Adapted from standard reference³ unless specified otherwise.**USES:****Primary uses:**

- *Gestational trophoblastic tumour
- *Rhabdomyosarcoma
- *Wilms' tumour

Other uses:

- *Ewing's sarcoma
- Ovarian germ cell tumour⁴
- Kaposi's sarcoma⁵
- Malignant melanoma⁶
- Testicular cancer^{4,7}

*Health Canada approved indication

SPECIAL PRECAUTIONS:**Contraindications:**

- recent or current infection with chicken pox or herpes zoster³

Caution:

- **Concurrent radiation therapy:** Severe reactions, including increased side effects, potentiation of radiation, and reactivation reactions have been reported. Gastrointestinal toxicity and marrow suppression can occur more frequently, especially with higher doses. Radiation myelitis has been reported.⁴ Severe oropharyngeal mucositis has been associated with concurrent therapy when radiation is directed towards the nasopharynx.^{3,4} Potentiation effects of radiation therapy include smaller radiation doses causing erythema and vesiculation,³ and rarely necrosis.⁴ Skin sequelae may progress more rapidly through the stages of tanning and desquamation with healing occurring in 4-6 weeks (compared to 2-3 months).³ Reactivation erythema has been reported in previously irradiated tissues, especially if the treatment interval is brief, but has also been described in therapy occurring months after radiation.⁴ Reactivation of radiation enteritis has also been described.⁴
- Hepatomegaly, ascites, and elevated AST levels have been noted in combination therapy of **right-sided Wilms' tumor**. It is not recommended to use dactinomycin concomitantly with radiation in the treatment of this disease, and particular caution is advised during treatment within the first two months after irradiation.³

Special populations:

- not recommended in children **under 6 months of age** due to an increased frequency of toxic effects³
- **Elderly** patients may experience an increased risk of myelosuppression, and consideration should be given to initiating therapy at the lower end of the dose range³

Carcinogenicity: Secondary malignancies, including leukemia, have been reported in patients with concurrent radiation and other agents.^{3,4,8,9}

Mutagenicity: Mutagenic in various *in vitro* and *in vivo* test systems, including human fibroblasts and leukocytes, and HELA cells. Clastogenic in mammalian *in vivo* chromosome tests.³

Fertility: no information found

Pregnancy: FDA Pregnancy Category D.³ There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).

Breastfeeding is not recommended due to the potential secretion into breast milk.³

SIDE EFFECTS:

The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important.^{10,11}

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in bold, italics	
allergy/immunology	allergic reactions (<1%)
	anaphylactoid reactions
blood/bone marrow/ febrile neutropenia	agranulocytosis
	anemia, including aplastic anemia (>10%)
	febrile neutropenia
	leukopenia ; nadir at 14-21 days, recovery within 21-25 days ⁴
	neutropenia (>10%); dose limiting ^{12,13}

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in bold, italics	
	pancytopenia
	reticulopenia
	thrombocytopenia (>10%); may be the first manifestation of myelosuppression, occurring 1-7 days after treatment; nadir at 12-21 days, recovery within 21-25 days ^{4,6}
constitutional symptoms	fatigue (>10%)
	fever
	lethargy
	malaise
dermatology/skin	extravasation hazard: vesicant ^{3,4}
	acne, acneiform eruptions
	alopecia (11%) ⁶ ; usually begins after 7-10 days, reversible; may involve the scalp and eyebrows ⁴
	erythema; occurs early at site of irradiation, may be followed rapidly by hyperpigmentation, and/or edema, desquamation, vesiculation, and rarely necrosis ⁴
	folliculitis; may extend down back, including buttocks ¹⁴
	pruritic maculopapular rash
	rash (37%, severe 26%); exacerbated by radiation or sun exposure (16%) ⁶
endocrine	growth retardation
gastrointestinal	emetogenic potential: moderate to high-moderate ^{12,13}
	abdominal pain
	anorexia
	cheilitis (inflammation of the lips)
	diarrhea (1-29%) ^{3,6} ; hold treatment until recovery ^{3,4}
	dysphagia (11%) ⁶
	esophagitis
	gastrointestinal ulceration
	glossitis
	mucositis (29-47%, severe 11%) ⁶ ; more severe with high doses combined with high doses of radiation therapy ⁴
	nausea and vomiting (29-79%) ⁶ ; usually occurs during the first few hours, ³ and can last up to 24 hours ⁴ ; can sometimes last up to 3 days and require hospitalization ⁶
	pharyngitis
	proctitis
	stomatitis ; dose limiting ^{3,12,13}
hepatobiliary/pancreas	ascites
	hepatic failure, usually reversible, sometimes fatal ³⁻⁵ ; see paragraph following Side Effects table
	hepatic veno-occlusive disease ³ ; sometimes fatal (particularly in children <4 years); may be associated with intravascular clotting disorder and multiorgan failure ^{4,7}

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in bold, italics	
	hepatitis
	hepatomegaly
infection	infection, unspecified (1-10%)
metabolic/laboratory	hypocalcemia
	liver function test abnormalities, unspecified
	renal function test abnormalities, unspecified
musculoskeletal	myalgia
pulmonary	pneumonitis
secondary malignancy	leukemia ^{3,4,8}
syndromes	flu-like syndrome; may occur 1 week after infusion and persist 1-3 weeks ⁷

Adapted from standard reference³ unless specified otherwise.

Hepatotoxicity: Ascites, hepatomegaly, hepatic veno-occlusive disease, hepatitis, and liver function test abnormalities have been reported, sometimes with fatal outcomes.^{3,5} Usual doses are more likely to produce hepatotoxicity in situations where additional stressors are placed on the liver (e.g., concomitant radiation).⁵

INTERACTIONS:

AGENT	EFFECT	MECHANISM	MANAGEMENT
halogenated inhalation anesthetics (enflurane, halothane) ³	increased hepatotoxicity	not specified	monitor liver function tests; use with caution
vaccines, live ³	increased risk of infection	decreased immune response may allow vaccine to produce infection	avoid vaccination with live vaccines

Bioassay procedures for the determination of antibacterial drug levels may be affected by dactinomycin.³

SUPPLY AND STORAGE:

Injection: Ovation Pharmaceuticals, Inc. supplies dactinomycin as 0.5 mg (500 mcg) vials of sterile lyophilized powder. Store at room temperature. Protect from light.³

For basic information on the current brand used at the BC Cancer Agency, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.

SOLUTION PREPARATION AND COMPATIBILITY:

For basic information on the current brand used at the BC Cancer Agency, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.

Additional information:

- Avoid use of sterile water containing preservatives (benzyl alcohol or parabens) for reconstitution as precipitate will result.³
- Compatible with D5W and saline solutions.³
- Avoid the use of in-line cellulose ester membrane filters for administration as partial removal of dactinomycin has been reported.^{3,4}

Compatibility: consult detailed reference

PARENTERAL ADMINISTRATION:

BCCA administration guideline noted in **bold, italics**

Subcutaneous ⁴	not used due to corrosive nature
Intramuscular ⁴	not used due to corrosive nature
Direct intravenous ^{12,13,15}	into tubing of running IV ; see Prevention and Management of Extravasation of Chemotherapy
Intermittent infusion ⁵⁻⁷	infuse over 10-15 minutes
Continuous infusion ¹⁶	has been used
Intraperitoneal	no information found
Intrapleural	no information found
Intrathecal	no information found
Intra-arterial	no information found
Intravesical	no information found
Regional isolation perfusion therapy ^{4,5}	has been used

DOSAGE GUIDELINES:

Refer to protocol by which patient is being treated. Numerous dosing schedules exist and depend on disease, response, and concomitant therapy. Guidelines for dosing also include consideration of absolute neutrophil count (ANC). Dosage may be reduced, delayed or discontinued in patients with bone marrow depression due to cytotoxic/radiation therapy or with other toxicities.

Adults:

For each two week course of therapy, maximum dose should not exceed **0.015 mg/kg** or 0.4-0.6 mg/m² IV once daily for 5 consecutive days.³

BCCA usual dose noted in **bold, italics**

<i>Intravenous:</i>	Cycle length: 2 weeks ¹² :	0.6 mg/m² once daily for 2 consecutive days starting on day 1 (total dose per cycle 1.2 mg/m²)
	2 weeks ¹³ :	0.5 mg/m² once daily for 2 consecutive days starting on day 8 (total dose per cycle 1 mg/m²)
	2 weeks ⁷ :	2.5 mg/m ² in divided doses over 1 week
	1-4 weeks ^{3,6,7} :	0.75-2 mg/m ² for one dose on day 1
	3 weeks ^{17,18} :	0.045 mg/kg for one dose on day 1
	3-6 weeks ⁷ :	0.4-0.6 mg/m ² once daily for 5 consecutive days

BCCA usual dose noted in ***bold, italics***

	n/a ^{3,5} :	<i>0.012 mg/kg</i> once daily for 5 consecutive days
	n/a ^{3,5} :	0.5 mg once daily for 2 consecutive days starting on day 1
	n/a ^{4,5,7} :	<i>1 mg/m²</i> for one dose on day 1
	n/a ⁵ :	<i>0.015 mg/kg</i> once daily for 5 consecutive days
<i>Concurrent radiation:</i>		reported to cause increased sensitivity to radiation therapy; reduce dose in patients who are receiving concurrent radiation therapy ^{3,4}
<i>Dosage in myelosuppression:</i>		modify according to protocol by which patient is being treated; if no guidelines available, refer to Appendix 6 "Dosage Modification for Myelosuppression"
<i>Dosage in renal failure:</i>		no adjustment required ³
<i>Dosage in hepatic failure:</i>		consider dose reduction in moderate to severe hepatic failure; may reduce dose by 30-50% for hyperbilirubinemia ³
<i>Dosage in dialysis:</i>		no information found

Children:

For each two week course of therapy, maximum dose should not exceed 15 mcg/kg or 0.4-0.6 mg/m² IV once daily for 5 consecutive days.³

<i>Intravenous:</i>	Cycle Length: n/a ^{3,5,7} :	<i>0.015 mg/kg</i> once daily for 5 consecutive days
	3-6 weeks ^{7,19} :	<i>0.015 mg/kg</i> or 0.4-0.6 mg/m ² once daily for 5 consecutive days
	n/a ⁵ :	<i>1 mg/m²</i> for one dose on day 1
	3-6 weeks ¹⁹ :	<i>0.045-0.06 mg/kg</i> for one dose
	3 weeks ¹¹ :	<i>0.023-0.045 mg/kg</i> for one dose, age dependent; maximum dose 2.5 mg

REFERENCES:

- MARTINDALE - The Complete Drug Reference (database on the Internet). Dactinomycin. Thomson MICROMEDEX®, 2008. Available at: <http://www.micromedex.com/>. Accessed 20 October 2008.
- National Institute for Occupational Safety and Health (NIOSH). Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. Cincinnati, Ohio: NIOSH - Publications Dissemination; September 2004. p. 31-40.
- Ovation Pharmaceuticals Inc. COSMEGEN® product monograph. Deerfield, Illinois; 19 August 2008.
- McEvoy GK, editor. AHFS 2008 Drug Information. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc. p. 1015-1018.
- DRUGDEX® Evaluations (database on the Internet). Dactinomycin. Thomson MICROMEDEX®, 2008. Available at: www.micromedex.com. Accessed 20 October 2008.
- Benjamin RS, Hall SW, Burgess MA, et al. A pharmacokinetically based phase I-II study of single-dose actinomycin D (NSC-3053). Cancer Treat Rep 1976;60(3):289-291.
- Rose BD editor. Dactinomycin. UpToDate 16.2 ed. Waltham, Massachusetts: UpToDate®; 2008.

8. Sandoval C, Pui C, Bowman L, et al. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. *J Clin Oncol* 1993;11(6):1039-1045.
9. Aung L, Gorlick RG, Shi W, et al. Second malignant neoplasms in long-term survivors of osteosarcoma. *Cancer* 2002;95(8):1728-1734.
10. Paul Hoskins MD. Personal communication. BC Cancer Agency Gynecology Tumour Group; 10 December 2008.
11. Jeff Davis MD. Personal communication. BC Cancer Agency Cancer Drug Manual Editorial Review Board; 9 December 2008.
12. BC Cancer Agency Gynecologic Oncology Tumour Group. (GOTDLR) BCCA Protocol Summary for Therapy for Low Risk Gestational Trophoblastic Cancer Using Dactinomycin and Methotrexate. Vancouver, British Columbia: BC Cancer Agency; 1 September 2008.
13. BC Cancer Agency Gynecologic Oncology Tumour Group. (GOTDHR) BCCA Protocol Summary for Therapy for High Risk Gestational Trophoblastic Cancer. Vancouver, British Columbia: BC Cancer Agency; 7 November 2006.
14. Perry MC, Yarbrow JW editors. *Toxicity of Chemotherapy*. Orlando, Florida: Grune & Stratton, Inc.; 1984.
15. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. *Blood* 2008;111(1):86-93.
16. Blumenreich MS, Woodcock TM, Richman SP, et al. A phase 1 trial of dactinomycin intravenous infusion in patients with advanced malignancies. *Cancer* 1985;56:256-258.
17. Arndt CA, Hawkins DS, Stoner JA, et al. Randomized phase III trial comparing vincristine, actinomycin, cyclophosphamide (VAC) with VAC/V topotecan/cyclophosphamide (TC) for intermediate risk rhabdomyosarcoma (IRRMS). D9803, COG study. *J Clin Oncol* 2007;25(18S):9509.
18. Arndt C, Hawkins D, Anderson JR, et al. Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide. *J Clin Oncol* 2004;22(10):1894-1901.
19. Pizzo P, Poplack D. *Principles and Practice of Pediatric Oncology*. 5th ed. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2006. p. 302-333,423,834,456-457.